Vertex gains expanded indication for Casgevy in children as young as two
· seekingalpha.com
Vertex’s Casgevy wins FDA approval for kids as young as 2 with sickle cell disease or beta thalassemia. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...